ECOR Stock Risk & Deep Value Analysis
electroCore, Inc.
Healthcare • Medical Devices
DVR Score
out of 10
What You Need to Know About ECOR Stock
We analyzed electroCore, Inc. using our deep value framework. Sign in to see our full verdict and DVR Score.
We ran ECOR through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Our risk assessment: Aggressive. Here's what we found.
ECOR Risk Analysis & Red Flags
What Could Go Wrong
The company's most critical risk is its inability to secure additional capital to sustain operations. With only $10.8M in cash and equivalents as of March 31, 2026, and a Q1 2026 net loss of $6.2M, its current burn rate suggests roughly 4-5 quarters of runway before requiring significant new funding, making insolvency or highly dilutive equity offerings a near-term inevitability without a major financial inflection point.
Risk Matrix
Overall
Aggressive
Financial
High
Market
Low
Competitive
Medium
Execution
Medium
Regulatory
Low
Red Flags
- ⚠
Cash balance of $10.8M (as of Mar 31, 2026) is precariously low relative to Q1 2026 net loss of $6.2M.
- ⚠
Q1 2026 net margin of -64.6% worsened compared to the previously cited -43.6%, indicating continued profitability challenges despite revenue growth.
- ⚠
Persistent negative Free Cash Flow and significant operating losses over multiple quarters.
Upcoming Risk Events
- 📅
Failure to Secure Funding (Q3/Q4 2026): Without new financing to supplement the current $10.8M cash balance, and given Q1 2026's $6.2M net loss, electroCore faces insolvency or highly dilutive equity raises within 2-3 quarters.
- 📅
Loss of Key Distribution Agreement (H1 2027): Should a material distribution agreement or partnership for gammaCore not be renewed or terminated, it could severely impact revenue growth, potentially reducing projected FY2027 revenue by 15-20%.
When to Reconsider
- 🚪
Exit if cash and cash equivalents drop below $7M without a clear, announced financing plan.
- 🚪
Sell if Q2 2026 reported GAAP net loss is greater than $7M, indicating an accelerating cash burn.
- 🚪
Exit if the company announces a share offering that increases the outstanding share count by more than 20% without a clear, immediate path to profitability.
Unlock ECOR Risk Analysis & Red Flags
Create a free account to see the full analysis
What Does electroCore, Inc. (ECOR) Do?
Market Cap
$78.98M
Sector
Healthcare
Industry
Medical Devices
Employees
73
electroCore, Inc., a bioelectronic medicine and general wellness company, provides non-invasive vagus nerve stimulation (nVNS) technology platform in the United States, the United Kingdom, and internationally. The company develops gammaCore, a prescription only handheld device intended for regular or intermittent use for the acute treatment of pain associated with migraine and episodic cluster headache, as well as for the treatment of hemicrania continua and paroxysmal hemicrania. It also develops Truvaga 350, a personal use consumer electronics general wellness product and Truvaga Plus, an, app-enabled general wellness product. It also offers non-invasive bioelectronic therapies for the treatment of chronic pain and wellness conditions. In addition, the company offers TAC-STIM for human performance and gammaCore Sapphire, a portable, reusable, rechargeable, and reloadable prescription medical device for various primary headache conditions. electroCore, Inc. was incorporated in 2005 and is headquartered in Rockaway, New Jersey.
Visit electroCore, Inc. WebsiteInvestment Thesis
If electroCore secures substantial, minimally dilutive financing (e.g., through a strategic partnership or debt offering) and continues its strong revenue growth trajectory (Q1 2026 at +42.64% YoY) while demonstrating a clear path to significantly narrowing its net loss from $6.2M per quarter, then the market could re-rate its valuation to reflect its large, untapped market opportunity for non-invasive migraine treatment, potentially reaching a 3-4x EV/Sales multiple and a significantly higher share price from its current ~$78M market cap. This is bullish because the market is currently heavily discounting its operational progress due to severe financial distress.
Is ECOR Stock Undervalued?
Unlock the full AI analysis for ECOR
Get the complete DVR score, risk analysis, and more
Unlock the full report
Create a free account to see the DVR score, risk flags, and AI analysis.
ECOR Price Targets & Strategy
12-Month Target
$15.00
Bull Case
$25.00
Bear Case
$1.00
Valuation Basis
Based on a 3.5x EV/Sales multiple applied to projected FY26 revenue of $40M, assuming successful (albeit dilutive) capital raise and sustained growth, leading to an implied market cap of $140M. Then, divided by current shares outstanding (~8.3M) adjusted for potential ~10-15% dilution.
Entry Strategy
Dollar-cost average between $8.00-$9.00 on dips, or after confirmation of a significant, non-dilutive financing event.
Exit Strategy
Take 50% profit at $15.00, consider full exit at $25.00 if financial health remains precarious. Stop loss at $6.00 if cash burn accelerates or funding fails.
Portfolio Allocation
2% for aggressive risk tolerance.
Price Targets & Strategy
Sign up free to unlock price targets and entry/exit strategies
Is ECOR Financially Healthy?
Profitability
Gross Margin
87.68%
Operating Margin
-41.97%
Net Margin
-44.08%
Return on Equity
-235.81%
Revenue Growth
31.90%
EPS
$-1.78
Balance Sheet
Current Ratio
1.38
Quick Ratio
1.11
Other
Beta (Volatility)
0.88
Does ECOR Have a Competitive Moat?
Sign in to unlockMoat Rating
🛡️ Narrow
Moat Trend
Stable
Moat Sources
2 Identified
The moat is primarily built on its patented technology and regulatory approvals. These provide a competitive edge in its niche, but the durability depends on continued R&D innovation, effective commercialization to build brand recognition, and securing broader reimbursement to establish switching costs for patients and providers.
Moat Erosion Risks
- •Patent expiry or successful challenges to existing IP could erode its core technological advantage.
- •Emergence of superior, equally safe, and cost-effective competing non-invasive or pharmacological therapies.
- •Limited reimbursement coverage restricting market access and adoption.
ECOR Competitive Moat Analysis
Sign up to see competitive advantages
ECOR Market Intelligence
Sentiment & Insider Activity
Social Sentiment
Neutral - cautious. Retail investors are likely divided between belief in product potential and concern over financial viability.
Institutional Sentiment
Neutral - no recent major analyst upgrades/downgrades or target changes from the provided data, suggesting a wait-and-see approach due to financial uncertainty.
Insider Activity (Form 4)
Director Thomas J. Errico bought 9,992 shares at $5.99 on 2026-05-21 and 8 shares on 2026-05-20, increasing direct ownership to 360,071 shares. Joshua S. Lev sold 3,000 shares for $19,500 on 2026-05-22, a relatively small transaction.
Options Flow
Normal options activity.
Earnings Intelligence
Next Earnings
Estimated early August 2026 (for Q2 2026 results)
Surprise Probability
Medium
Historical Earnings Pattern
Likely volatile; stock price reaction typically depends heavily on cash position updates and forward guidance regarding financial stability rather than just revenue beats.
Key Metrics to Watch
Competitive Position
Top Competitor
CVRX (Barostim)
Market Share Trend
Gaining - in its specific niche of non-invasive VNS for headache disorders, but overall market share in neuromodulation is small.
Valuation vs Peers
Trading at a discount to growth-oriented medical device peers on an EV/Sales basis but cannot be valued on traditional P/E due to persistent losses. Its high growth rate for a medical device company might justify a higher multiple if financial health improves.
Competitive Advantages
- •Proprietary non-invasive vagus nerve stimulation (nVNS) technology with strong patent protection for gammaCore.
- •FDA approvals for multiple indications (migraine, cluster headache) providing regulatory validation and market access.
- •Established clinical efficacy data supporting product claims.
Market Intelligence
Sign up free to unlock sentiment, earnings intel, and peer analysis
What Could Drive ECOR Stock Higher?
Near-Term (0-6 months)
- •Q2 2026 Earnings Release (estimated early August 2026): Key metrics to watch are cash balance, net loss trajectory, and any new financing announcements to alleviate current liquidity concerns.
- •Strategic Partnership Announcement (Q3/Q4 2026): A significant partnership with a major pharmaceutical or medical device company for distribution or co-development could provide critical non-dilutive funding or market access.
Medium-Term (6-18 months)
- •Expanded Reimbursement Coverage (H1 2027): Securing broader reimbursement for gammaCore for additional indications (e.g., specific headache types) in major markets beyond current coverage, potentially adding $5M-$10M in annual revenue.
- •New Indication FDA Approval (H2 2027): FDA approval for a new, large market indication for gammaCore (e.g., post-traumatic headache) could significantly expand TAM and drive a new wave of adoption, potentially adding $15M-$25M to annual revenue run-rate.
Long-Term (18+ months)
- •Sustainable Positive Free Cash Flow (FY2028-FY2029): Achieving consistent positive free cash flow, indicating the business model is self-sustaining and no longer reliant on external financing, which could re-rate the stock to a traditional healthcare multiple.
- •International Market Leadership (FY2029-FY2030): Establishing significant market share for non-invasive neuromodulation in key international markets (e.g., EU, Asia) through strategic partnerships and direct sales channels, driving annual revenue past $100M.
Catalysts & Growth Drivers
Sign up free to see growth catalysts
What's the Bull Case for ECOR?
- ✓
Watch cash and cash equivalents: Crossing $15M without substantial new debt/equity implies better cash management or an impending funding event.
- ✓
Watch gross margin: If gross margin (previously 87%) begins to decline significantly, it indicates pricing pressure or rising production costs.
- ✓
Watch partnership announcements: A major distribution or co-development deal could signal a turning point in commercialization and financial stability.
Bull Case Analysis
Sign up free to see the bull case
Competing with ECOR
See how electroCore, Inc. compares to related companies
| Company | Market Cap | DVR Score | P/E | Revenue | Profit Margin | Rev Growth | |
|---|---|---|---|---|---|---|---|
electroCore, Inc. ECOR | $79.0M | 2.5 | — | — | -44.1% | 31.9% | |
AbbVie Inc ABBV | $381.1B | 0.1 | 104.8 | $15.0B | 5.8% | 9.5% | Compare → |
Johnson & Johnson JNJ | $557.1B | 1.0 | 26.5 | — | 21.8% | 7.9% | Compare → |
Eli Lilly and Co LLY | $965.0B | 0.5 | 52.6 | — | — | — | Compare → |
Pfizer Inc PFE | $146.4B | 4.0 | 19.5 | $62.6B | 11.8% | 1.4% | Compare → |
UnitedHealth Group Inc UNH | $365.5B | 0.3 | 30.3 | $447.6B | 2.7% | 9.7% | Compare → |
📊 Explore More Stock Analysis
Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential with our AI-powered analysis.
How electroCore, Inc. Makes Money
electroCore, Inc. develops and commercializes gammaCore, a non-invasive handheld medical device that delivers vagus nerve stimulation (nVNS) to treat neurological conditions. Its primary focus is on relieving acute pain associated with migraine and cluster headaches. The company generates revenue through the sale of gammaCore devices and recurring sales of associated disposable electrodes or subscription services, targeting patients with a prescription and healthcare providers. The business model leverages proprietary, FDA-approved technology to offer a non-drug alternative for pain management.
Read Full Business Model BreakdownFAQ
What is the DVR Score for electroCore, Inc. (ECOR)?
As of June 10, 2026, electroCore, Inc. has a DVR Score of 2.5 out of 10, placing it in the "Risk Trap" category. This score is generated by our AI-powered deep value analysis framework that evaluates growth potential, financial health, competitive moat, and risk factors.
What is the market capitalization of electroCore, Inc.?
electroCore, Inc.'s market capitalization is approximately $79.0M. The company operates in the Healthcare sector within the Medical Devices industry.
What ticker symbol does electroCore, Inc. use?
ECOR is the ticker symbol for electroCore, Inc.. The company trades on the NCM.
What is the risk level for ECOR stock?
Our analysis rates electroCore, Inc.'s overall risk as Aggressive. This assessment considers execution risk, market risk, financial risk, competitive risk, and regulatory risk. For a full breakdown, see the risk analysis section above.
Is electroCore, Inc.'s revenue growing?
electroCore, Inc. has reported revenue growth of 31.9%. The company is showing strong top-line momentum.
Is ECOR stock profitable?
electroCore, Inc. has a profit margin of -44.1%. The company is currently unprofitable.
How often is the ECOR DVR analysis updated?
Our AI-powered analysis of electroCore, Inc. is refreshed regularly to incorporate the latest financial data, market conditions, and news. The most recent update was on June 10, 2026.
Important Disclaimer – Not Financial Advice
Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided on this page for ECOR (electroCore, Inc.) should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.
All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research, consider your financial situation, and consult with a qualified financial advisor before making any investment decisions.